Therapeutic effect of pEgr-IL18-B7.2 gene radiotherapy in B16 melanoma-bearing mice

Human Gene Therapy

Volumn 18, Issue 4, 2007, Pages 323-332

  Yang, Jianzheng ^a   Jin, Guanghui ^b   Liu, Xiaodong ^a,c   Liu, Shuzheng ^a  

^a JILIN UNIVERSITY   (China)

^b XIAMEN UNIVERSITY   (China)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD86 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 18; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; GENE THERAPY; IMMUNOGENICITY; MELANOMA B16; MELANOMA CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; RADIATION DOSE; TUMOR IMMUNITY; TUMOR LOCALIZATION; X IRRADIATION;

ANIMALS; ANTIGENS, CD86; COMBINED MODALITY THERAPY; GENE THERAPY; INTERLEUKIN-18; KILLER CELLS, NATURAL; MACROPHAGES, PERITONEAL; MELANOMA, EXPERIMENTAL; MICE; PLASMIDS; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR NECROSIS FACTOR-ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 34248163599     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2006.133     Document Type: Article

References (43)

1. BOYD, M., MAIRS, R.J., KEITH, W.N., ROSS, S.C., WELSH, P., AKABANI, G., OWENS, J., VAIDYANATHAN, G., CARRUTHERS, R., DORRENS, J., and ZALUTSKY, M.R. (2004). An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radiostatin and harnessing radiation-mediated bystander effects. J. Gene Med. 6, 937-947.
2. CAO, R., FARNEBO, J., KURIMOTO, M., and CAO, Y. (1999). Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB J. 13, 2195-2202.
3. CARRENO, B.M., and COLLINS, M. (2002). The B7 family of ligands and its receptors: New pathways for costimulation and inhibition of immune responses. Annu. Rev. Immunol. 20, 29-53.
4. CHO, D., KIM, T.G., LEE, W., HWANG, Y.I., CHO, H.I., HAN, H., KWON, O., KIM, D., PARK, H., and HOUH, D. (2000). Interleukin-18 and the costimulatory molecule B7.1 have a synergistic anti-tumor effect on murine melanoma: Implication of combined immunotherapy for poorly immunogenic malignancy. J. Invest. Dermatol. 114, 928-934.
5. FARRAR, J.J., SIMON, P.L., KOOPMAN, W.J., and FULLER-BONAR, J. (1978). Biochemical relationship of thymocyte mitogenic factor and factors enhancing humoral and cell-mediated immune responses. J. Immunol. 121, 1353-1360.
6. GAJEWSKI, T.F., FALLARINO, F., UYTTENHOVE, C., and BOON, T. (1996). Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: Superiority of B7.1 over B7.2 for active tumor immunization. J Immunol. 156, 2909-2917.
7. GILL, R.G., COULOMBE, M., and LAFFERTY, K.J. (1996). Pancreatic islet allograft immunity and tolerance: The two-signal hypothesis revisited. Immunol. Rev. 149, 75-96.
8. GILLIGAN, M.G., KNOX, P., WEEDON, S., BARTON, R., KERR, D.J., SEARLE, P., and YOUNG, L.S. (1998). Adenoviral delivery of B7.1 (CD80) increases the immunogenicity of human ovarian and cervical carcinoma cells. Gene Ther. 5, 965-974.
9. GRIDLEY, D.S., and SLATER, J.M. (2004). Combining gene therapy and radiation against cancer. Curr. Gene Ther. 4, 231-248.
10. HALLAHAN, D.E., MAUCERI, H.J., SEUNG, L.P., DUNPHY, E.J., WAYNE, J.D., HANNA, N.N., TOLEDANO, A., HELLMAN, S., KUFE, D.W., and WEICHSELBAUM, R.R. (1995). Spatial and temporal control of gene therapy using ionizing radiation. Nat. Med. 1, 786-791.
11. HIKOSAKA, S., HARA, I., MIYAKE, H., HARA, S., and KAMIDONO, S. (2004). Antitumor effect of simultaneous transfer of interleukin-12 and interleukin-18 genes and its mechanism in a mouse bladder cancer model. Int. J. Urol. 11, 647-652.
12. HODGE, D.L., SUBLESKI, J.J., REYNOLDS, D.A., BUSCHMAN, M.D., SCHILL, W.B., BURKETT, M.W., MALYGUINE, A.M., and YOUNG, H.A. (2006). The proinflammatory cytokine interleukin-18 alters multiple signaling pathways to inhibit natural killer cell death. J. Interferon Cytokine Res. 26, 706-718.
13. JIN, G.H., JIN, S.Z., LIU, Y., XU, R.M., YANG, J.Z., PAN, X.N., and LIU, S.Z. (2005). Therapeutic effect of gene-therapy in combination with local X-irradiation in a mouse malignant melanoma model. Biochem. Biophys. Res. Commun. 330, 975-981.
14. KIM, J.K., CHOI, S.H., KIM, C.O., PARK, J.S., AHN, W.S., and KIM, C.K. (2003). Enhancement of polyethylene glycol (PEG)-modified cationic liposome-mediated gene deliveries: Effects on serum stability and transfection efficiency. J. Pharm. Pharmacol. 55, 453-460.
15. KUFE, D., and WEICHSELBAUM, R.R. (2003). Radiation therapy: Activation for gene transcription and the development of genetic radiotherapy-therapeutic strategies in oncology. Cancer Biol. Ther. 2, 326-329.
16. LESPAGNARD, L., METTENS, P., DE SMEDT, T., BAZIN, H., URBAIN, J., LEO, O., and MOSER M. (1998). The immune response induced in vivo by dendritic cells is dependent on B7-1 or B7-2, but the inhibition of both signals does not lead to tolerance. Int. Immunol. 10, 295-304.
17. LI, W.H., and YANG, Y.G. (1991). Measurement of lymphokines. In Practical Experimental Techniques in Basic Medicine. S.L. Gong and M. Zhang, eds. (Jilin Science and Technology Press, Changchun, China) pp. 189-196.
18. MARINO, E., and CARDIER, J.E. (2003). Differential effect of IL-18 on endothelial cell apoptosis mediated by TNF-α and Fas (CD95). Cytokine 22, 142-148.
19. MATULONIS, U., DOSIOU, C., FREEMAN, G., LAMONT, C., MAUCH, P., NADLER, L.M., and GRIFFIN, J.D. (1996). B7.1 is superior to B7.2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity: Further evidence that B7.1 and B7.2 are functionally distinct. J. Immunol. 156, 1126-1131.
20. MICALLEF, M.J., TANIMOTO, T., KOHNO, K., IKEDA, M., and KURIMOTO, M. (1997). Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma. Cancer Res. 57, 4557-4563.
21. NING, S., LAIRD, D., CHERRINGTON, J.M., and KNOX, S.J. (2002). The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat. Res. 157, 45-51.
22. OSAKI, T., HASHIMOTO, W., GAMBOTTO, A., OKAMURA, H., ROBBINS, P.D., KURIMOTO, M., LOTZE, M.T., and TAHARA, H. (1999). Potent antitumor effects mediated by local expression of the mature form of the interferon-γ inducing factor, interleukin-18 (IL-18). Gene Ther. 6, 808-815.
23. PAGES, F., BERGER, A., HENGLEIN, B., PIQUERAS, B., DANEL, C., ZINZINDOHOUE, F., THIOUNN, N., CUGNENC, P.H., and FRIDMAN, W.H. (1999). Modulation of interleukin-18 expression in human colon carcinoma: Consequences for tumor immune surveillance. Int. J. Cancer 84, 326-330.
24. PARK, C.C., MOREL, J.C., AMIN, M.A., CONNORS, M.A., HARLOW, L.A., and KOCH, A.E. (2001). Evidence of IL-18 as a novel angiogenic mediator. J. Immunol. 167, 1644-1653.
25. PENTCHEVA-HOANG, T., EGEN, J.G., WOJNOONSKI, K., and ALLISON, J.P. (2004). B7.1 and B7.2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity 21, 401-413.
26. ROSENBERG, J.S., GILMAN, S.C., and FELDMAN, J.D. (1982). Regulation of rat B cell responses by T cell subsets and interleukin 2. J. Immunol. 129, 996-1001.
27. SAMOILOVA, K.A., BOGACHEVA, O.N., OBOLENSKAYA, K.D., BLINOVA, M.I., KALMYKOVA, N.V., and KUZMINIKH, E.V. (2004). Enhancement of the blood growth promoting activity after exposure of volunteers to visible and infrared polarized light. I. Stimulation of human keratinocyte proliferation in vitro. Photochem. Photobiol. Sci. 3, 96-101.
28. SHI, F., RAKHMILEVICH, A.L., HEISE, C.P., OSHIKAWA, K., SONDEL, P.M., YANG, N.S., and MAHVI, D.M. (2002). Intratumoral injection of interleukin-12 plasmid DNA, either naked or in complex with cationic lipid, results in similar tumor regression in a murine model. Mol. Cancer Ther. 1, 949-957.
29. SUN, Y., WANG, J.M., and LUO, Y.Z. (2002). Effects of total flavones from Epimedium L on IL-2 and NK activity in immunodepressant mice. Chin. Traditional Herbal Drugs 33, 635-637.
30. TAKAHASHI, T., HIRANO, N., TAKAHASHI, T., CHIBA, S., YAZAKI, Y., and HIRAI, H. (2000). Immunogene therapy against mouse leukemia using B7 molecules. Cancer Gene Ther. 7, 144-150.
31. WEICHSELBAUM, R.R., HALLAHAN, D.E., SUKHATME, V.P., and KUFE, D.W. (1992). Gene therapy targeted by ionizing radiation. Int. J. Radiat. Oncol. Biol. Phys. 24, 565-567.
32. WEICHSELBAUM, R.R., HALLAHAN, D.E., BECKETT, M.A., MAUCERI, H.J., LEE, H., SUKHATME, V.P., and KUFE, D.W. (1994). Gene therapy targeted by radiation preferentially radiosensitizes tumor cells. Cancer Res. 54, 4266-4269.
33. WEICHSELBAUM, R.R., KUFE, D.W., ADVANI, S.J., and ROIZMAN, B. (2001). Molecular targeting of gene therapy and radiotherapy. Acta Oncol. 40, 735-738.
34. WENDTNER, C.M., NOLTE, A., MANGOLD, E., BUHMANN, R., MAASS, G., CHIORINI, J.A., WINNACKER, E.L., EMMERICH, B., KOTIN, R.M., and HALLEK, M. (1997). Gene transfer of the costimulatory molecules B7.1 and B7.2 into human multiple myeloma cells by recombinant adeno-associated virus enhances the cytolytic T cell response. Gene Ther. 4, 726-735.
35. WEN, S.Y., WANG, X.H., LIN, L., GUAN, W., and WANG, S.Q. (2004). Preparation and property analysis of a hepatocyte targeting pH-sensitive liposome. World J. Gastroenterol. 10, 244-249.
36. WIGGINTON, J.M., LEE, J.K., WILTROUT, T.A., ALVORD, W.G., HIXON, J.A., SUBLESKI, J., BACK, T.C., and WILTROUT, R.H. (2002). Synergistic engagement of an ineffective endogenous antitumor immune response and induction of IFN-γ and Fas-ligand-dependent tumor eradication by combined administration of IL-18 and IL-2. J. Immunol. 169, 4467-4474.
37. WU, C.M., LI, X.Y., and HUANG, T.H. (2004). Anti-tumor effect of pEgr-IFNγ gene-radiotherapy in B16 melanoma-bearing mice. World J. Gastroenterol. 10, 3011-3015.
38. XIA, D., LI, F., and XIANG, J. (2004). Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity. Cancer Biother. Radiopharm. 19, 322-330.
39. + Th1 killer lymphocytes. Br. J. Cancer 89, 1876-1884.
40. YANG, G., HELLSTROM, K.E., HELLSTROM, I., and CHEN, L. (1995). Antitumor immunity elicited by tumor cells transfected with B7.2, a second ligand for CD28/CTLA-4 costimulatory molecules. J. Immunol. 154, 2794-2800.
41. YANG, J.Z., JIN, G.H., TIAN, M., PAN, X.N., JIN, S.Z., and LIU, S.Z. (2004). Cloning and sequencing of mouse B7.2 gene and construction of its recombinant plasmids. J. Jilin Univ. (Med. Ed.) 30, 334-336.
42. YANG, Y., LIU, S.Z., and FU, S.B. (2004). Anti-tumor effects of pNEgr-mIL-12 recombinant plasmid induced by X-irradiation and its mechanisms. Biomed. Environ. Sci. 17, 135-143.
43. ZIPS, D., KRAUSE, M., HESSEL, F., WESTPHAL, J., BRUCHNER, K., EICHELER, W., DORFLER, A., GRENMAN, R., PETERSEN, C., HABEREY, M., and BAUMANN, M. (2003). Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation. Anticancer Res. 23, 3869-3876.